权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

13TSB_ENDANI: A pen side test for Schmallenberg virus exposure in sheep and cattle

13TSB_ENDANI：羊和牛中施马伦贝格病毒暴露的笔侧测试

基本信息

批准号：
BB/L011387/1
负责人：
Janet Daly
金额：
$ 12.36万
依托单位：
University of Nottingham
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2013
资助国家：
英国
起止时间：
2013 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=BB%2FL011387%2F1
关键词：
13TSB_ENDANI pen side test Schmallenberg

项目摘要

This project's primary objective is to develop a pen-side test for Schmallenberg virus (SBV) to a commercialisation stage.The test will be able to be used by Farmers and Veterinarians to determine whether an animal has been infected with SBV in a matter of minutes and at a greatly reduced cost to the existing tests performed by central laboratories. The project will use next generation phage-display technology to comprehensively screen serum from SBV infected animals for antibodies that react to the virus. The peptides on the virus that produce a robust antibody response in infected animals will be selected and manufactured for used as the antigen for the serological test. Lateral flow device tests based on these peptides will be developed by Forsite diagnostics who manufacture several of these types of tests currently. They will produce a small-scale production of these tests for comparison for sensitivity and specificity against the existing laboratory-based tests. These tests will then be field trialled for ease of use, performance in the field and likely use by a large veterinary practice group. A secondary aim of the project is the identification of which parts of the virus are important in generating a host immune response. This information will be created as a result of the initial screening and will be able to be used in the design of the next generation of vaccines and tests for this virus. The vaccine due to be released in 2013 is a crude killed virus preparation and it is unlikely that there will be any way to distinguish vaccinated from naturally infected animals. This is likely to be a future requirement for export to non-EU countries meaning there will be a need for more sophisticated vaccine and test strategies in the near future.

该项目的主要目标是将施马伦贝格病毒（SBV）的笔侧检测开发到商业化阶段。该检测将能够被农民和兽医用于在几分钟内确定动物是否感染了SBV，并且与中心实验室进行的现有检测相比，成本大大降低。该项目将使用下一代噬菌体展示技术，全面筛选SBV感染动物的血清中与病毒反应的抗体。将选择并生产在感染动物中产生稳健抗体应答的病毒上的肽，用作血清学试验的抗原。基于这些肽的侧流装置测试将由Forsite诊断公司开发，该公司目前生产几种此类测试。他们将小规模生产这些测试，以与现有的实验室测试进行灵敏度和特异性比较。然后，这些测试将进行现场试验，以便于使用，在现场的性能和可能的使用由一个大型兽医实践组。该项目的第二个目的是确定病毒的哪些部分在产生宿主免疫反应方面是重要的。这些信息将作为初步筛选的结果产生，并将能够用于设计下一代疫苗和该病毒的测试。将于2013年发布的疫苗是一种粗制的灭活病毒制剂，不太可能有任何方法区分接种疫苗的动物和自然感染的动物。这可能是未来出口到非欧盟国家的要求，这意味着在不久的将来将需要更复杂的疫苗和测试策略。